Abstract: Primary liver cancer（PLC） is one of the most common malignant tumors that seriously threaten the health of Chinese. In China, PLC is currently the second most prevalent cause of tumor death and the fourth most common type of malignancy, with 75% ~ 85% of cases being hepatocellular carcinoma （HCC）. Since 2023, the American National Comprehensive Cancer Network （NCCN） Hepatobiliary Duct Clinical Practice Guidelines have been published in a new layout, describing HCC and cholangiocarcinoma separately, which have distinctly different biological behaviors. The 2023 V1 edition of the NCCN Clinical Practice Guidelines for Hepatobiliary Carcinoma （hereafter referred to as the new edition of the guidelines） was first published on March 10. The new edition of the guidelines has more updates than the 2022 V5 edition of the NCCN Clinical Practice Guidelines for Hepatobiliary Ductal Carcinoma regarding HCC, covering more than ten important topics such as screening, diagnosis, and treatment principles, which are of significant reference for China and detailed in this article.

Key words: hepatocellular carcinoma, NCCN, guideline, interpretation

摘要： 原发性肝癌是严重威胁中国人健康的最常见恶性肿瘤之一。据最新中国恶性肿瘤统计数据,原发性肝癌是目前中国第4位常见恶性肿瘤和第2位肿瘤致死病因,其中75%~85%为肝细胞癌（HCC）。自2023年起,美国《NCCN肝胆管临床实践指南》以全新版面发布,将生物学行为明显差异的HCC与胆管癌分别叙述。其中2023年V1版《NCCN肝细胞癌临床实践指南》（下文简称新版《指南》）于3月10日首次发布,相较2022年V5版《NCCN肝胆管癌临床实践指南》中有关HCC的具体内容,新版《指南》有了较多更新,涉及筛查、诊断和治疗等十余个重要问题,对中国的肝癌治疗有借鉴价值,本文就此进行解读。

关键词: 肝细胞癌, 国家综合癌症网络, 指南, 解读